GlassScriptPhysician profile
Helena A Yu
NPI 1871791665
$198,392.28
in general payments reported to CMS, 2019-2025
28 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $17K · 2021: $25K · 2022: $18K · 2023: $32K · 2024: $55K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $88K · Travel and Lodging: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,190 · Honoraria: $6,655 · Food and Beverage: $1,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $87,892.91 |
| Travel and Lodging | $11,145.23 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,190.00 |
| Honoraria | $6,655.00 |
| Food and Beverage | $1,356.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $38,549.84 | 2019-2025 | Tagrisso |
| Takeda Pharmaceuticals U.S.A., INC. | $26,892.18 | 2022-2024 | |
| Daiichi Sankyo INC. | $19,452.67 | 2019-2024 | |
| Astrazeneca Uk Limited | $18,459.42 | 2019-2025 | Tagrisso, Datroway |
| Janssen Biotech, INC. | $16,934.11 | 2021-2025 | Rybrevant |
| Janssen Scientific Affairs, LLC | $15,847.50 | 2021-2025 | Rybrevant |
| Janssen Global Services, LLC | $11,060.00 | 2020-2025 | Rybrevant |
| Merck Sharp & Dohme LLC | $7,687.28 | 2023 | |
| Gilead Sciences, INC. | $7,150.00 | 2022-2025 | |
| Abbvie INC. | $5,737.50 | 2023-2024 | |
| Novocure INC. | $5,098.57 | 2024 | Optune Lua (Novottf-200t) |
| Blueprint Medicines Corporation | $4,788.00 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $4,370.85 | 2024-2025 | |
| Ipsen Bioscience INC. | $4,350.00 | 2023 | |
| Taiho Oncology, INC. | $2,196.11 | 2022-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,100.00 | 2025 | |
| Rigel Pharmaceuticals, INC. | $1,869.54 | 2025 | Gavreto |
| Array Biopharma INC | $1,540.61 | 2024 | Braftovi, Mektovi, Lorbrena |
| Orion Corporation | $1,510.60 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $1,240.00 | 2023 | |
| Puma Biotechnology, INC. | $907.50 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $650.00 | 2020 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helena Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.